RBC Raises Roche to 'Outperform' Amid AI Energy Demand

RBC Capital Markets has upgraded Roche Holdings AG (CH1499059XXX) to an outperform rating with a target price of 400 Swiss francs, citing sustained growth in its core business and an underappreciated pipeline of future products. While the company’s market valuation remains close to its all-time high, analyst Trung Huynh notes that the current valuation still leaves room for further revaluation, particularly as the pharmaceutical sector continues to benefit from strong demand and innovation. Roche’s ability to drive operational efficiency and expand its product portfolio could support long-term shareholder returns, despite the elevated stock price.